Ulm-type Hereditary Angioedema - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱ 7 min read ✅ Medically reviewed
```html Ulm‑type Hereditary Angioedema: Comprehensive Medical Guide

Ulm‑type Hereditary Angioedema: A Comprehensive Medical Guide

Overview

Ulm‑type hereditary angioedema (HAE‑Ulm) is an extremely rare, autosomal‑dominant form of hereditary angioedema that is characterized by recurrent, painful swelling (angioedema) without the presence of urticaria (hives). Unlike the more common C1‑esterase inhibitor (C1‑INH)–deficient types (HAE‑I & HAE‑II), HAE‑Ulm occurs in individuals who have normal C1‑INH levels and function. The disease is named after the German city of Ulm, where the first families were described.

  • Who it affects: Both males and females of any age, though symptoms often start in late childhood or early adulthood.
  • Prevalence: Estimated at ≈1 in 1,000,000 worldwide, making it one of the rarest HAE subtypes.[1][2]
  • Genetics: Caused by pathogenic variants in the F12 gene (encoding coagulation factor XII) in most reported families, but other gene loci (e.g., PLG, ANGPT1, KNG1) have been implicated in ultra‑rare cases.[3]

Symptoms

Symptoms are caused by excessive bradykinin production, which leads to increased vascular permeability. The pattern can be highly variable even within a single family.

Typical clinical manifestations

  • Subcutaneous swelling: Swelling of the limbs, face, trunk, or genital area; often begins abruptly and can last 2–5 days.
  • Gastrointestinal attacks: Crampy abdominal pain, nausea, vomiting, and/or diarrhea. May mimic an acute abdomen and sometimes lead to unnecessary surgery.
  • Upper airway edema: Swelling of the tongue, lips, or larynx; can be life‑threatening.
  • Periorbital and perioral edema: Puffy eyes or swollen mouth without itching.

Less common or atypical features

  • Genital or anal swelling.
  • Facial cellulitis‑like erythema (without true infection).
  • Unexplained weight gain from fluid accumulation.
  • Prodromal sensations (tingling, burning) before swelling develops.

Importantly, unlike allergic angioedema, HAE‑Ulm attacks are not associated with urticaria, itching, or response to antihistamines, corticosteroids, or epinephrine.

Causes and Risk Factors

Genetic cause

Pathogenic variants in F12 (most common) increase the activity of factor XII, which triggers the kallikrein‑kinin system and leads to excess bradykinin. Other rare genes (PLG, ANGPT1, KNG1, MYOF) have been identified in families lacking F12 mutations.

Inheritance pattern

  • Autosomal‑dominant with high penetrance (≈80–90%).
  • One affected parent can transmit the mutation to 50 % of offspring.

Environmental or lifestyle triggers

  • Physical trauma (including dental work, surgery).
  • Stress or emotional upset.
  • Hormonal changes – estrogen‑containing oral contraceptives or hormone replacement therapy can exacerbate attacks.
  • Infections, especially upper respiratory.
  • Mechanical irritation (tight clothing, pressure on limbs).

Who is at higher risk?

  • Individuals with a known family history of HAE‑Ulm.
  • Women taking estrogen‑containing products.
  • People with uncontrolled stress or frequent dental procedures without prophylaxis.

Diagnosis

Because laboratory findings are normal, diagnosis relies on a combination of clinical history, family pedigree, and genetic testing.

Step‑by‑step diagnostic approach

  1. Detailed clinical interview – frequency, location, duration of attacks, triggers, and lack of response to antihistamines or steroids.
  2. Family history assessment – constructing a three‑generation pedigree to identify autosomal‑dominant transmission.
  3. Laboratory screening – C4 level and C1‑INH antigen/function are usually normal in HAE‑Ulm, which helps exclude C1‑INH‑deficient types.
  4. Genetic testing – Targeted sequencing of F12 and, if negative, a broader hereditary angioedema gene panel (including PLG, ANGPT1, KNG1, etc.).
  5. Functional assays (research setting) – Measurement of plasma kallikrein activity or bradykinin levels after provocation, but these are not standard clinical tools.

Key diagnostic criteria (per International HAE Working Group)

  • Recurrent angioedema without urticaria.
  • Normal C1‑INH antigen and function.
  • Normal C4 level (or transiently low during attacks).
  • Confirmed pathogenic variant in a known HAE‑Ulm gene.

Differential diagnosis

  • Allergic (IgE‑mediated) angioedema.
  • Acquired angioedema due to C1‑INH deficiency.
  • Medication‑induced bradykinin angioedema (e.g., ACE inhibitors).
  • Autoimmune or infectious causes of swelling.

Treatment Options

Treatment aims to shorten attacks**, prevent future episodes, and protect the airway**. Management follows three pillars: on‑demand therapy, short‑term prophylaxis, and long‑term prophylaxis.

On‑demand (acute) therapy

  • C1‑INH concentrate (plasma‑derived or recombinant) – Works even though C1‑INH is normal; doses 20 U/kg IV are recommended.[4]
  • Icatibant (FirazyrÂź) – A bradykinin B2‑receptor antagonist; 30 mg subcutaneously, repeat after 6 h if needed.[5]
  • Ecallantide (KalbitorÂź) – Kallikrein inhibitor; 30 mg subcutaneously, may repeat after 6 h.
  • For airway edema, intubation or emergency cricothyrotomy may be required before medication takes effect.

Short‑term prophylaxis (STP)

Used before predictable triggers (e.g., dental work, surgery).

  • C1‑INH concentrate 1–2 hours before procedure (20 U/kg IV).
  • Icatibant 30 mg SC 1–2 hours pre‑procedure (off‑label in some regions).
  • High‑dose antihistamines and steroids are NOT effective for HAE‑Ulm and should not replace targeted therapy.

Long‑term prophylaxis (LTP)

Recommended for patients with frequent (>1 per month) or severe attacks, or those unable to self‑administer acute therapy.

  • Lanadelumab (TakhzyroÂź) – Subcutaneous monoclonal antibody against plasma kallikrein; 300 mg every 2 weeks (or every 4 weeks after stabilization). Proven to reduce attack frequency by >90 % in HAE‑C1‑INH; emerging data support efficacy in HAE‑Ulm.[6]
  • Berotralstat (OrladeyoÂź) – Oral kallikrein inhibitor 150 mg daily; convenient for patients preferring oral therapy.
  • Plasma‑derived C1‑INH prophylaxis 60–80 U/kg IV 2–3 times per week (off‑label for HAE‑Ulm but used in practice).

Lifestyle and supportive measures

  • Carry an “angioedema emergency kit” (icatin‑bat or C1‑INH) and know how to self‑administer.
  • Avoid known triggers (estrogen, ACE inhibitors).
  • Maintain a medical alert bracelet.
  • Educate family members, school staff, or coworkers about the condition and emergency steps.

Living with Ulm‑type Hereditary Angioedema

Daily management tips

  • Track attacks: Use a smartphone app or diary to note date, location, possible trigger, severity, and medication response. This data helps the physician tailor therapy.
  • Medication schedule: Keep prophylactic meds on a routine schedule; set alarms if needed.
  • Hydration & low‑salt diet: Reduces the risk of abdominal attacks linked to fluid shifts.
  • Stress reduction: Techniques such as mindfulness, yoga, or counseling can lower trigger frequency.
  • Dental care: Inform dentists of the diagnosis; schedule prophylactic C1‑INH or icatibant before invasive procedures.
  • Travel preparedness: Carry extra medication, a copy of the prescription, and a letter from your physician explaining the condition for customs.

Psychosocial aspects

Recurrent swelling can cause anxiety, embarrassment, and social withdrawal. Consider the following:

  • Join patient support groups (e.g., HAE International, National Angioedema Society).
  • Seek mental‑health counseling if attacks impact quality of life.
  • Inform schools or employers about necessary accommodations (e.g., permission to self‑inject).

Prevention

Because attacks are bradykinin‑mediated, reducing exposure to triggers and maintaining adequate prophylaxis are the primary preventive strategies.

  • Avoid estrogen‑containing products: Choose progestin‑only contraception or non‑hormonal methods.
  • Discontinue ACE inhibitors and ARBs: These drugs increase bradykinin levels.
  • Vaccinations (influenza, COVID‑19, pneumococcal) to lessen infection‑related attacks.
  • Prompt treatment of infections – especially upper respiratory infections.
  • Regular follow‑up: Review prophylaxis efficacy and adjust dosing annually or after any change in attack patterns.

Complications

If not promptly managed, HAE‑Ulm can lead to serious complications:

  • Airway obstruction: Laryngeal edema can cause rapid respiratory compromise and is the leading cause of HAE‑related mortality.
  • Abdominal emergencies: Misdiagnosed as appendicitis or bowel obstruction, leading to unnecessary surgery.
  • Chronic pain or adhesions: Repeated abdominal attacks may cause scar tissue.
  • Psychological distress: Chronic disease burden can precipitate depression or anxiety.
  • Medication‑related side effects: Allergic reactions to plasma‑derived products, injection site reactions with subcutaneous agents.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Swelling of the tongue, lips, or throat that makes breathing or swallowing difficult.
  • Sudden voice change, hoarseness, or a feeling of choking.
  • Severe abdominal pain with vomiting, especially if you suspect intestinal obstruction.
  • Rapidly spreading facial or neck edema.
  • Any angioedema episode that does not improve after 1–2 doses of your prescribed on‑demand medication.

While waiting for emergency services, self‑administer your prescribed acute therapy (e.g., icatibant or C1‑INH) if you are able, and inform the medical team that you have HAE‑Ulm.

Key Takeaways

  • Ulm‑type HAE is a rare, autosomal‑dominant, bradykinin‑mediated angioedema with normal C1‑INH levels.
  • Recurrent, painful swelling of skin, gastrointestinal tract, or airway defines the disease; itching and urticaria are absent.
  • Diagnosis requires clinical suspicion, normal C1‑INH labs, and confirmation of a pathogenic F12 (or related) gene variant.
  • Effective on‑demand treatments include icatibant, C1‑INH concentrate, and ecallantide; prophylaxis options include lanadelumab, berotralstat, or regular C1‑INH infusions.
  • Lifestyle modifications, trigger avoidance, and a personalized emergency plan are essential for daily living.
  • Rapid airway swelling is a medical emergency—know the warning signs and act without delay.

References

  1. World Allergy Organization. “Hereditary Angioedema: Guidelines and Consensus Reports.” WAO Journal, 2022.
  2. Mayo Clinic. “Hereditary Angioedema – Types & Causes.” Updated 2023. https://www.mayoclinic.org
  3. Craig, T. et al. “Genetic Landscape of Hereditary Angioedema.” J Allergy Clin Immunol, 2021;147(4):1422‑1434.
  4. Cleveland Clinic. “C1‑Esterase Inhibitor Concentrate for Acute Angioedema.” 2023. https://my.clevelandclinic.org
  5. FDA. “Icatibant (Firazyr) Prescribing Information.” 2022.
  6. Lanadelumab Phase III Study (HELP). “Efficacy in Hereditary Angioedema.” New England Journal of Medicine, 2020.
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References